Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
The prevalence of left ventricular hypertrophy (LVH) rises with severity of hypertension (HT), age, and obesity. Its prevalence ranges from 20% in mildly hypertensive patients to almost 100% in those with severe or complicated HT. However, the diagnosis of LVH is not straightforward, and the definitions and criteria used in clinical studies lack consistency. While many factors play a role in the onset and progression of LVH, blood pressure (BP) is recognized as a central factor. Twenty-four-hour BP measurements are more closely related to LVH than conventional BP readings taken in the clinician's office. Increased renin-angiotensin system (RAS) activity also plays an important role in the development of LVH, and various studies show a correlation between plasma renin activity and left ventricular mass (LVM). LVH is a recognized marker of HT-related target organ damage, and a strong and independent risk factor for adverse cardiovascular (CV) outcomes. CV risk increases with increasing LVM, and decreases with regression of LVH in response to antihypertensive treatment. Therefore the detection, prevention, and reversal of LVH are important goals in HT management. Most antihypertensive drugs can attenuate BP and LVH. However, each drug class may induce LVH regression to a different extent and these extents seldom correlate with the degree of BP reduction achieved. Data from the few large comparative studies in this area suggest that certain classes of antihypertensive drugs and/or their combinations are more effective than others. In particular, calcium channel blockers and drugs that target the RAS, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), appear to have a specific effect on LVH, independent of BP reduction. Guidelines, therefore, have recommended these drug classes for the treatment of hypertensive patients with LVH.
Ruilope
Luis M
LM
Hospital 12 de Octubre, Avda. de Córdoba s/n, Madrid, Spain. ruilope@ad-hocbox.com
Schmieder
Roland E
RE
D000959:Antihypertensive Agents / Q000191:economics / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D002318:Cardiovascular Diseases / Q000191:economics / Q000209:etiology* / Q000401:mortality / Q000503:physiopathology / Q000517:prevention & control; D015897:Comorbidity; D003362:Cost-Benefit Analysis; D017048:Health Care Costs; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy / Q000191:economics / Q000401:mortality / Q000503:physiopathology; D017379:Hypertrophy, Left Ventricular / Q000175:diagnosis / Q000188:drug therapy / Q000191:economics / Q000209:etiology* / Q000401:mortality / Q000503:physiopathology; D016896:Treatment Outcome
D000959:Antihypertensive Agents